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Biodegradable polymers arenowused inmore thanadozen
marketed controlled-release drug products ranging from
bothhydrophilic andhydrophobic smallmolecules to small
water-soluble peptides.[1,2] After the development of thecommercial one-month polymer depot for human growth
hormone, the Nutropin Depot (Alkermes/Genentech),[3]
and its subsequent removal from the market,[4] injectable
polymer depots are currently limited tomolecules without
significant tertiary structure (i.e., occurring in proteins).
Key challenges to expand polymer depot formulations
have involved: a) protein instability,[5–10] b) difficulties
associated with use of organic solvents,[11] c) manufactur-
ing costs,[4] d) difficulties to control the release kinetics
(particularly the initial burst),[12–14] and large needle
sizes.[15]
Toaddress anumberof theaforementionedchallenges in
polymer depot development, we have recently developed
an entirely new encapsulation method based on polymer
healing,[16,17] which shifts the encapsulation paradigm for
largemolecules inbiodegradablepolymers (e.g., poly(lactic-
co-glycolic acids (PLGAs)) from an organic solvent-based
process to that occurring entirely in an aqueousDOI: 10.1002/mabi.201300323
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sensitive agents (e.g., proteins and DNA[9]) involves first
creating a drug-free polymer platform (e.g., microspheres),
which contains an interconnecting pore network. The
porous microspheres are then submerged in an aqueous
solution containing the biomacromolecule desired for
encapsulation at temperatures (T) typically below the
polymer glass transition temperature (Tg) of the poly-
mer.[17,20] Under mild agitation to minimize inter-particle
healing (i.e., aggregation), the T is raised > hydrated Tg to
initiate intra-polymer healing of the pores. Polymer surface
pores seal off from the external solution initiating self-
healing (SH) encapsulation and those pores within the
polymer become steadily more spherical.[17] As the
technique relies on the natural tendency of polymers to
self-heal defects above theirTg,wehave termed thisprocess
‘‘Self-healing (SH) microencapsulation.’’ This process can
occur whether the polymer is hydrated or dry, follows
Williams–Landel–Ferry time temperature superposition
behavior, and is strongly influenced by the pore size and
polymer end-capping.[19]
We have devised two types of SH encapsulation
processes to date – that is, passive loading during which
no attempt is made to increase partitioning of the
biomacromolecule to be loaded from the aqueous solution
into the polymer, and active loading during which there is
an additional driving force to cause partitioning into the
polymer to encapsulate with high efficiency. The latter
technique is akin to remote loading of doxorubicin in
DOXIL stealth liposomes by precipitation of the drug as it
diffuses into the empty liposome.[17] The feasibility of the
encapsulation method was demonstrated by showing the
potential for high drug loading,[18] high encapsulation
efficiency,[18,21,22] low initial burst,[18] excellent protein
stability,[18,21,22] the ability to terminally sterilize the pre-
formedpolymerbefore loading,[21] andcontrolled releaseof
biomacromolecules in vitro and in vivo.[18,21,22] However,
there are several important parameters that require careful
examination in order to better understand both the
potential and limitations of SH encapsulation.
Therefore, herein we first examined the influence of
various pore-forming excipients on the loading of bovine
serum albumin (BSA) and the related initial release and
stability of the protein. Then,we examined the influence of
a key parameter controlling the SH polymer performance –
porosity (e) – on the passive SH of a model enzyme,
lysozyme. Porosity of pre-formed PLGA microspheres was
manipulated by incorporating into the polymer various
levels of a pore-forming agent (MgCO3),
[14,23] varying the
inner-water phase content during double-emulsion sol-
vent-evaporation,[24–26] and adjusting the concentration of
carrier solvent to form the microparticle.[24,27,28] The
resulting microspheres were thoroughly evaluated for
their e, morphology, SH encapsulation characteristics, asMacromol. Biosci. 20
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.comwell as enzyme stability and release behavior. This data
below describes in full detail the e effects expanding from
our initial disclosure of the significant effect of e on SH
loading of proteins.[18] The pore structure of the polymer
will affect both passive and active loading strategies by
creating the pathway for both entry and distribution of the
encapsulating agent as well as a template for polymer
healing. The encapsulation, morphological, stability, and
release behavior below provides previously unknown and
important insightastohowporositycanbemanipulatedby
varyingmicrosphere formulation parameters and how this
affects novel microspheres formed by SH.2. Experimental Section
2.1. Materials
PLGAwith an inherent viscosity (i.v.)¼0.57 dL g1 (50:50, PLGA DL
LOW IV, Lot No. W3066-603, lauryl ester end group, 51 kD) was
purchased from Lakeshore Biomaterials, (Birmingham, AL), for-
merly Alkermes. a,a-Trehalose dihydrate was purchased from
Pfanstiehl (Waukegon, IL)andpolyvinylalcohol (9–10kDa,80%mol
hydrolyzed) was purchased from Sigma–Aldrich (St. Louis, MO).
Magnesium carbonate (MgCO3), BSA, fraction V, and lysozyme
(from chicken egg white) were purchased from Sigma–Aldrich.
Coomassie Plus Protein Reagent was purchased from Pierce
(Thermo Fisher Scientific, Rockford, IL). All other common salts,
reagents, and solvents unless otherwise specified were purchased
from Sigma–Aldrich.
2.2. Methods
2.2.1. Conjugating BSA to a pH-Insensitive Fluorescent
Coumarin
1.2 g of BSAwas dissolved in 40mL of 0.2M sodiumbicarbonate pH
4.5 and to thiswas added2mLof 10mgmL1 7-methoxycoumarin-
3-carbonyl azide in DMSO while stirring. The solution was stirred
continuously at room temperature in darkness for 90min. To
quench the reaction, 4mL of 1.5M hydroxylamine hydrochloride
was added and then the solution was extensively dialyzed using a
25 000 MWCO membrane against dd H2O at 4 8C.
2.2.2. Formulation of Self-Healing PLGA Microspheres
with Varying e for BSA Loading
For blank particles to be loaded with BSA–coumarin, an emulsion
wasfirst createdbyadding150mL of aporosigen in1 PBSaqueous
solution (300mg BSA, 269mg of dextran, 55mg of dextran, 300mg
Kollidon PVP, 50mg Kollidon PVP, 500mg sucrose, 250mg sucrose,
20mg PEG MW 175000, 10mg PEG MW 175000, 50mg gelatin
(TypeA), or 50mggelatin (TypeB) in1gPBS) to700mgPLGA (50:50,
0.19 dL g1) that had been dissolved in 1mL of CH2Cl2 in a small
glass test tube. The aqueous/polymer solutions were immediately
homogenized in an ice water bath at 10 000 rpm for 1.0min
creating the first emulsion. Two milliliters of 5% PVA (9–10 kDa,
80% hydrolyzed) was then added to the first emulsion and the13, 13, 1700–1710
bH & Co. KGaA, Weinheim 1701
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1702mixture vortexed at a high setting for 15 s, creating the second
emulsion and the resulting solution was injected into 100mL of
0.5% PVA (9–10kDa, 80% hydrolyzed) solution under continuous
stirring. Microspheres were stirred 3h at room temperature, and
collected using sieves (Newark Wire Cloth Company, Newark, NJ)
to separate by size and washed thoroughly with dd H2O to
remove residual PVA, porosigen, and solvent. The particles were
sieved to 20–45 and 45–90 mm fractions and immediately freeze
dried. The 45–90 mm size range was used for BSA–coumarin
encapsulation.
2.2.3. Formulation of Self-Healing PLGA Microspheres
with Varying e for Lysozyme Loading
For eachof the three setsofvariating formulations (MgCO3 content,
inner water phase volume, polymer concentration), an emulsion
was first created using trehalose dihydrate solution (500mg in 1 g
PBS, pH 7.4) that was added to PLGA (50:50, 0.57 dL g1) that had
been dissolved in 1mL of CH2Cl2 in a 5–6mL syringe. Accordingly,
for varying MgCO3 content, 200 mL trehalose dihydrate solution
was added to 320mg PLGA with 0, 4.8, 14.4, or 39.5mg MgCO3
suspended in the polymer solution before emulsification. For
varying innerwater phasevolume, 25, 100, 200, or 350mL trehalose
dihydrate solution was added to 320mg PLGA, and for varying
polymer concentration, 200 mL trehalose dihydrate solution was
added to 200, 260, 320, or 400mg PLGA with 4.8mg MgCO3
suspended in the polymer solution before emulsification. The
aqueous/polymer solutions were immediately homogenized in an
icewater bath at 17 000 rpmfor 1.0min creating thefirst emulsion.
Two milliliters of 5% PVA (9–10kDa, 80% hydrolyzed) was then
added to the first emulsion and the mixture homogenized at
6000 rpm for 25 s (20 s for varying MgCO3 content particles),
creating the second emulsion and the resulting solution was
injected into 100mL of 0.5% PVA (9–10kDa, 80% hydrolyzed)
solutionundercontinuousstirring.Microsphereswerestirred3hat
room temperature, and collected with sieves (Newark Wire Cloth
Company) to separate by size andwashed thoroughlywith ddH2O
to remove residual PVA, sugar, salt, and solvent. The particleswere
sieved to 20–63 and and 63–90 mm fractions immediately freeze
dried. The 20–63 mm size range was used for this study, as this
encompasses a common size distribution used in commercial
products and is large enough to avoid phagocytosis but small
enough to be injected through small size needles.
2.2.4. Microencapsulation of BSA–Coumarin
in Self-Healing PLGA Microspheres
Approximately1mLof205mgmL1 4 8CBSA–coumarin inPBSwas
added to approximately 100mg of blank particles and the
microsphere/protein solutions were incubated at 4 8C for 44h on
a rocking platform, and then transferred to a 43 8C incubator on a
slow speed rotary shaker for 22h.Microsphereswere removed and
washed thoroughly with dd H2O, centrifuging at 3200 rpm for
5min to collect themicrospheres after each of 10washes, and then
freeze dried. Healing times require typically 12–48h due to the
slow process of polymer chain reptation into the pores during
healing. The times can be reduced by increasing temperature,
adding polymer plasticizers, or decreasing polymer molecular
weight.[17,18]Macromol. Biosci. 201
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PLGA Microspheres
Approximately 1mL of 250mgmL1 4 8C lysozyme solution was
added to approximately 80mg of blank particles and the
microsphere/protein solutions were incubated at 4 8C for 72h on
a rocking platform, and then transferred to a 43 8C incubator on a
slow speed rotary shaker for 46h.Microsphereswere removed and
washed thoroughly with dd H2O, centrifuging at 3 800 rpm for
5min to collect themicrospheres after each of 10washes, and then
freeze dried.
2.2.6. Determination of Microsphere Loading, Release
Kinetics, and Residual Protein
For analysis of loading and residual protein after the release study,
approximately 4mg of dry microspheres were dissolved in
approximately 1.5mL of acetone, and the protein insoluble in
thesolventwassedimentedbycentrifugationat13 200 rpmfor10–
15min, and the supernatant removed. This extraction was
repeated three times, and the residual acetone was removed via
evaporation. The protein sediment was dissolved in PBST for
analysis.
For the release study, 1.0mL of PBST (PBSþ0.02% Tween 80), pH
7.4 was added to approximately 4–10mg of microspheres and
incubated at 37 8C. Release mediumwas removed and assayed for
protein content at each time point and replaced by fresh media.
For determination of soluble lysozyme content in the release
media and in the initial loading assays, a Coomassie protein assay
was run, using Coomassie Plus Protein Reagent (Thermo Scientific
Pierce) and measuring the absorbance at 595nm. For assay of
soluble lysozymemonomer remaining in theparticle, solubleBSA–
coumarin loading, soluble BSA–coumarin in the releasemedia, and
soluble BSA–coumarin remaining in the particle, the reconstituted
proteinafterpolymerremovalaboveorprotein in thereleasemedia
was analyzed by using SE-HPLC (Tosoh Biosciences TSKgel
G3000SWxl) using a guard column (Shodex Protein KW-G), with
amobile phase of 0.05Mpotassiumphosphate, 0.2 MNaCl, pH7.0 at
an isocratic flow rate of 0.9mLmin1. The absorbance at 215 and
280nmwasmeasured for lysozyme, and thefluorescencedetection
at 480nm emission (384nm excitation) was measured for BSA–
coumarin.
Insoluble lysozyme was recovered after removing all soluble
lysozyme by centrifugation and washing with 1 PBST. The
collected water-insoluble protein was then dissolved in 6M urea,
1mM EDTA, 10mM DL-dithiothreitol (Cleland’s reagent) (DTT), and
afterbrief vortexingandassaying theproteinusingCoomassiePlus
Protein Reagent as above. Standards were analyzed in the same
denaturing and reducing solution.
2.2.7. Determination of the e of Self-Healing
Microspheres
Porosity measurements on blank particles were made by Porous
Materials, Inc. (Ithaca, NY) using an AMP-60K-A-1 mercury
porosimeter, generating pore volume versus pressure data. The
pore volume was reported as amount of volume per gram (cc g1).
Total microparticle volume was calculated as the sum of the
pore volume and the polymer volume, where the polymer density3, 13, 1700–1710
& Co. KGaA, Weinheim www.MaterialsViews.com
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Figure 1. The effect of the concentration of the i.w. phase
porosigen on % loading of coumarin-labeled BSA. All
formulation parameters were identical except for the identity
and concentration of the i.w. phase porosigen in 1 g PBS, pH 7.4,
which was either 270mg dextran (), 55mg dextran (o), 300mg
Kollidon (PVP) (~), 50mg Kollidon (PVP) (~), 500mg sucrose (&),
250mg sucrose (&), 20mg PEG (^), 10mg PEG (^), 50mg gelatin
type A (!), 50mg gelatin type B (—), and 300mg BSA ( ).
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porosimetry sample were used to calculate the pore volume.
Porosity was calculated as the quotient of pore volume to total
microparticle volume. Pressure associated with microsphere
packing and surface wetting, before mercury intrusion into the
pores had taken place, was not calculated into the final pore
volume. An example plot generated by the instrument to
determine the pore intrusion volume is shown in Supporting
Information, Figure S1.
2.2.8. Activity of Lysozyme
Lysozyme was extracted from the microspheres and dissolved in
PBST, pH 7.4, at approximately 8.5 ( 1)mgmL1. At the same time,
standard solutions were dissolved in the same buffer at the same
fixed concentration. For analysis, 0.15mL of soluble protein
solution was combined with 0.15mL of 1.5mgmL1 Micrococcus
lysodeikticus in 1 PBS, pH 7.4 and the absorbance at 450nm was
monitored every 30 s for a period of 5min. The activity was
calculated using the decrease in absorbance for the linear portion
(between 0.5 and 3.0min) assuming one unit of enzyme activity
will reduce theDA450nmby0.001/min. Specificactivity is defined in
units of activity per mg of protein and is given as % of the specific
activity of the native, standard lysozyme. The actual amount of
solublemonomer lysozyme in the solutionwas determined via SE-
HPLC and was used for the specific activity calculations.
2.2.9. Scanning Electron Microscopy
Surface images of microspheres were taken after a brief gold
coating (60 s) usingaHitachi S3200Nscanningelectronmicroscope
at voltages ranging from 5 to 10kV.3. Results and Discussion
3.1. Determining the Effects of Excipient Loading on
Self-Healing Loading, and Initial Release and
Stability of BSA
Pores form naturally in PLGAmicrospheres prepared by in-
liquid hardening processes (e.g., water-in-oil-in-water
emulsion-solvent evaporation) owing to the carrier organic
solvent employed to dissolve the polymer and the aqueous
inner water phase commonly used to form the primary
emulsion. During drying in liquid, the organic solvent is
removedwith simultaneouspolymerphase shrinkageand/
or water exchange, and upon final drying, any water and
organic solvent remaining is removed to all but residual
levels creating the pores within the dry polymer. In control
studies, we first used the inherent e of the polymer to
attempt to load protein by healing, but no significant
protein could enter the polymer for encapsulation (data not
shown). Then, we added various water-soluble excipients
into the polymer microspheres (including a protein, as is
normally encapsulated by the water-in-oil-in-water emul-
sion method) at varying levels in hopes of creating a
percolating pore network, and recorded the loading ofMacromol. Biosci. 20
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.comcoumarin–BSA by SH encapsulation. As shown in Figure 1,
irrespective of several excipients types, we observed the
general trend that more BSA–coumarin could be loaded as
the concentration of excipient in the innerwater phasewas
increased. A possible explanation could be that increased
excipient leads to increasing space (i.e., porosity) in the
polymer matrix for protein entry.
After a short 7-d release study, the remaining BSA–
coumarinwas recoveredandanalyzed (Figure2).Of the four
formulations with high loading (i.e., loading above 0.75%
w/w), only that which used BSA as the porosigen had near
complete recovery of the loaded BSA–coumarin. This result
suggests that theBSAmayhavehelped to stabilize theBSA–
coumarin by helping buffer the acidic solution pH or
through providing additional interface-competing mole-
cules, as has been reported previously.[23,28] For the other
formulations of higher drug load (sucrose and dextrose
formulations), a significant amount (up to 40%) of the
protein was not recovered after 7 d of release incubation,
suggestive of insoluble protein aggregation.3.2. Creating Self-Healing PLGA Microspheres with
Interconnected Pore Networks of Varying e
Aswe saw abovewith the affect of adjusting pore-forming
content, which no doubt affects polymer e, we next sought
to systematically study the influence of e on encapsulation
and microsphere performance. In addition, as BSA has a13, 13, 1700–1710
bH & Co. KGaA, Weinheim 1703
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Figure 2. Mass balance of recovered BSA–coumarin after loading
and subsequent 7 d release. Dark bars represent the protein
released in the first 7 d of release, while the gray bars represent
the protein recovered after digestion of the remaining particles. All
protein released/recovered is normalized by the amount of protein
loaded. Blank particles were prepared using 150mL of i.w. phase
(above) in 1 g PLGA (50:50, i.v.¼0.19 dL g1) in 1mL CH2C12, with all
particles between 20 and 90mm.N¼ 3.
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1704significant tendency towardaggregationduring release,we
employedanothermodelprotein, lysozyme, tomore readily
evaluate the influence of this parameter e. Finally, as we
found earlier,[18] it is easier to obtain higher drug loading
withhighermolecularweight PLGAs, andsoweemployedaFigure 3. Effect of base content on pre-loaded and lysozyme-loaded
theoretical loading of base were created and loading in lysozyme sol
SEM images were taken before (A–D) and after closing (E–H). Formul
varying amounts of theoretical loading of MgCO3 (w/w): A,E) 0%, B
Supporting Information, Figure S4 for enlarged version.
Macromol. Biosci. 201
 2013 WILEY-VCH Verlag GmbHmedium molecular weight PLGA of 51 kDa in place of the
lower molecular weight PLGA.
To create porous microspheres for SH encapsulation, a
percolating pore-network is necessary for the entering
biomacromolecule to reach deep within the polymer for
release[18] and pores must not become too large (<3mm
have found to work well)[18] otherwise full healing time
becomes prohibitively long.[17] Percolation during micro-
particle formation is achieved with incorporation of a
simple osmotic agent (e.g., a sugar such as trehalose) or a
pore-former such as MgCO3, the latter of which reacts with
acid in the polymer (e.g., residual acids) to create osmotic
salts and/or gaseous CO2.
3.2.1. Effect of Formulation Variables on Self-Healing
Microsphere Morphology
Self-healing PLGA microspheres were prepared by varying
base content, aqueous inner water phase volume, and
polymer solution concentration, as shown in Figure 3, and
Supporting Information, Figures S2,S3. All four SH for-
mulations that incorporated differing amounts of pore-
forming MgCO3 (0, 1.5, 4.3, and 11.0% w/w) had a
surprisingly similar surface morphology (Figure 3A–D)
(enlarged version available as Supporting Information,
Figure S4A–D), although the amount of surface pores
appeared to increasewith the amount of base encapsulated
and also those surface pores visibly decreased slightly in
size with increasing base content.
Similarly, the surface morphology of four blank for-
mulations prepared with differing amounts of inner water
phase (25, 100, 200, and 350 mL of 500mg trehalose
dihydrate in 1 g 1 PBS, pH7.4) all had a similar appearance
to one another (Supporting Information, Figure S2A–D)
except for the formulation prepared with the lowest i.w.microparticle morphology. Four PLGA formulations with differing
ution was conducted at 4 8C for 72 h before healing at 42 8C for 46h.
ations used trehalose in PBS (pH 7.4) in the inner water phase with
,F) 1.5%, C,G) 4.3%, and D,H) 11.0%. White scale bars¼ 10mm. See
3, 13, 1700–1710
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Information, Figure S2A). The four blank formulations that
were created using differing concentrations of PLGA in the
organic phase (200, 260, 320, and 400mg PLGA in 1mL
CH2Cl2) had similar surfacemorphologies, but the pore size
slightly decreased with increasing polymer concentration
(Supporting Information, Figure S3A–D).
3.2.2. Effect of Formulation Variables on Mercury
Intrusion Volume and e of Self-Healing Microspheres
The e of the dry SH microspheres was calculated from the
intrusion volume, which was determined by mercury
porosimetry (Supporting Information, Figure S1). A very
large quantity of polymer sample was consumed with the
testing by the vendor at significant cost, and thus only one
test was run and there is no statistical variance. Porosity
was calculated as the percentage of pore volume to the
entire volume of the microspheres.
The intrusionvolumepergramshoweda similar trendas
the MgCO3 content: generally increasing with increasing
base content, although a slight decrease was seenwith the
highest base content. This intrusion volume per gram was
1.20 (0.0% MgCO3), 1.44 (1.5% MgCO3), 1.76 (4.3% MgCO3),
and 1.57 cc g1 (11% MgCO3). As seen in Table 1, these e
measurements were 60.0% (0.0% MgCO3), 64.3% (1.5%
MgCO3), 68.8% (4.3% MgCO3), and 66.2% (11% MgCO3).
Similarly, the intrusion volume per gram generally
increased with increasing inner water phase volume,
though a slight decrease was seen in the formulation withTable 1. Effect of formation variables on self-healing microsphere p
Method of
adjusting porosity
in formulation
Variable in
formulation
Porosity of
self-healing
microspheres
[%]
Varying base content 0% MgCO3 60.0
1.5% MgCO3 64.3
4.3% MgCO3 68.8
11% MgCO3 66.2
Varying inner water
phase volume
25 mL 49.5
100 mL 60.6
200 mL 64.0
350 mL 59.7
Varying polymer
concentration
200mg in 1mL 65.2
260mg in 1mL 61.0
320mg in 1mL 72.7
400mg in 1mL 64.6
a)All data reported as mean SEM (n¼3); formulation conditions
remainingþ insoluble remaining; no soluble aggregate in residual sam
Macromol. Biosci. 20
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.comthe highest volume level. The intrusion volume per gram
was 0.78 (25mL), 1.23 (100mL), 1.43 (200mL), and 1.18 cc g1
(350 mL), corresponding to the following e values: 49.5%
(25 mL), 60.6% (100 mL), 64.0% (200 mL), and 59.7% (350 mL).
Thus, as the both excipient level increased and the
volumeof innerwaterphasevolumeincreased, theporosity
seemed to increaseuntil somecritical valuewas reached.At
thatpoint, theporositydecreased.Onepossibleexplanation
for this was that too much aqueous phase was present at
some point prior to the microparticle hardening, allowing
theporosigen tobe releasedout of themicroparticle quicker
than for the other formulations. Thus, by the end of the
hardening phase, such particlesmay actually have had less
water uptake due to a lower osmotic gradient between the
microparticle and the outer water phase, leading to a less
porous particle. Similarly, the higher amount of inner
aqueousphasemayhaveprovidedagreater surface area for
the organic phase pockets tomigrate to, increasing the rate
of phase separationandhardening, and thusdecreasing the
overall porosity.
With changes in polymer concentration, the intrusion
volume per gram showed no distinct trend. The intrusion
volumes were 1.50 (200mg), 1.25 (260mg), 2.13 (320mg),
and 1.46 cc g1 (400mg), corresponding to porosities of
65.2% (200mg), 61.0% (260mg), 72.7% (320mg), and 64.6%
(400mg). A complicating factor in the latter data is that the
amount of base suspended in the polymer (instead of base
loading)wasfixedaspolymer concentrationwas increased.
Opposing factors (base content, initial organic solvent level,roperties.a)
28-d
lysozyme
release [%]
Monomeric
enzyme
remaining
[%]
Insoluble
enzyme
remaining
[%]
Mass
balance
[%]b)
30.4 0.7 57 2 4 1 92 2
41.3 0.5 47 1 3 1 91 1
51 4 46 1 3 1 99 4
57 4 51 1 1.4 0.1 110 4
30 3 76 4 11 2 117 5
25.9 0.3 64 3 6 1 96 3
33 2 62 2 5 1 100 3
24.5 0.6 55 1 5 1 85 1
34.4 0.3 55 2 4 1 93 2
20.6 0.8 74 2 6 1 100 2
46.6 0.5 42 2 6 3 95 3
57 2 30 2 3 1 89 2
listed in Section 2; b)Mass balance¼ 28-d releaseþmonomeric
ples.
13, 13, 1700–1710
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1706anddegreeofparticle shrinkage) appeared tobe responsible
for the absence of an expected or observed trend.Porosity (Vpore / VTotal) (%)
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Figure 4. Effects of pre-loaded PLGA microparticle formulation
parameters on subsequent lysozyme loading (%w/w) via self-
healing encapsulation. Twelve total formulations were prepared,
investigating the effect on loading from varying amounts of
theoretical MgCO3 content, volumes of inner water phase
solution, or polymer concentration: Self-healing formulations
were created with A) differing levels of MgCO3 suspended in
the organic phase with 200mL inner water phase volume and
320mgmL1 polymer concentration, B) differing volumes of inner
water phase volume with no MgCO3 and 320mgmL1 polymer
concentration, and C) differing amounts of PLGA (50:50, i.v.¼0.57
dL g1) in 1mL CH2Cl2 with suspended 4.8mg MgCO3 and 200mL
inner water phase volume. Open symbols are replotted from
Reinhold et al.[1] for completeness.3.3. Self-Healing Encapsulation of Lysozyme
The above SH microspheres were submerged in 250mg
mL1 aqueous lysozyme at 4 8C for 72h to allow the protein
to enter the polymer pore-network before healing the pores
at 43 8C for 48h. The effects of various e-varying SH
formulations onmicrospheremorphology, loading, release,
and stability of lysozyme are described below.
3.3.1. Morphology of Self-Healed Microspheres
After the pore closing/encapsulation step, all microspheres
with varying levels of MgCO3 had very similar fully healed
morphologies, with the highest base content (11%w/w)
having a slightly rougher surface (Figure 3E–H). Similarly,
healed microspheres prepared from varying inner water
phase volume also healed well with indistinguishable
surfaces (Supporting Information, Figure S2E–H). For the
microspheres prepared with varying polymer concentra-
tion (Supporting Information, Figure S3E–H), thenumber of
visible pores on the surface after healing appeared to
increase with polymer concentration as well, suggesting
that there was incomplete pore closing with high polymer
concentration (400mg in 1mL CH2Cl2) formulation (Sup-
porting Information, Figure S3H).
3.3.2. Effect of Formulation Parameters and Polymer e on
Loading of Lysozyme
As reported before,[18] increasing e at constant polymer
concentration from50 to 70% shows a steady, apparently
somewhat linear, increase in protein loading. Addition of
values from different polymer concentrations to the
loading versus e plot (Figure 4) also supports the positive
correlation between the two variables, although linearity
may occur only over a limited range. The highest e value
(>70%) showed a decrease in expected loading. Additional
data would be necessary to confirm this observation,
although certainly at some level of e the loading is logically
expected to decrease (i.e., no loading is possible as e
approaches unity). The increase in loading with e up to a
point is easily rationalized based on the expectation that
more available pores in the polymer matrix available for
loading will allow more external protein solution to enter
the polymer before healing. Interestingwas the x-intercept
of 47% in Figure 4, which is expected to have some
relationship with the lower percolation threshold of the
microspheres,[28] was significantly higher than the
expected percolation threshold values (e.g., <35%). This
result also suggests that if formulationswerepreparedwith
even lower e that thesedatawouldnotbeexpected to fall on
the best fit line.Macromol. Biosci. 201
 2013 WILEY-VCH Verlag GmbHThe loading as a function of various pore-determining
variables is also displayed in Figure 5. The most significant
changes were recorded for varyingMgCO3 and inner water
phase levels (Figure 5A,B) affecting the loading by as much
as 8-fold changes in protein loading. It is important to
point out that the drops in loading for formulations
prepared with the highest level of base and inner water
phase content, 11% and 350mL, respectively, were also
associated with similar drops in polymer e. This resulted in
maximal loading and e for the formulations prepared with
the 4.3% MgCO3 and 200mL levels. It should be noted that
200mLmL1 has long-been known as the rough upper limit
on phase volume ratio before significant loss in encapsula-
tion efficiency by the conventional W/O/W method.[29]
3.3.3. Effect of Formulation Parameters and Polymer e
Estimated Fraction of Pores Utilized for Self-Healing
Loading
By assuming equivalent partitioning of the protein
between external aqueous loading solution and the
internal microparticle pores, a fraction of pores utilized
for SH loading was estimated, as shown in Figure 6. Very
interesting was the insensitivity of formulation variables
on the fraction of pores utilized (mostly 20–25%) and most
of the pores (>65%) apparently were still available for3, 13, 1700–1710
& Co. KGaA, Weinheim www.MaterialsViews.com
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Figure 5. Enzyme loading as a function of porosity for SH-microspheres preparedwith varying formulation parameters. Triangles represent
varying theoretical base content microspheres (differing amounts of MgCO3 in the organic phase: 0, 1.5, 4.3, and 11.0%,), circles represent
varying inner water phase volumemicrospheres (differing volumes of inner water phase solution (trehalose in PBS, pH 7.4): 25, 100, 200, and
350 mL), and squares represent varying polymer concentration microspheres (differening amounts of PLGA (50:50, i.v.¼0.57 dL g1) in 1mL
CH2Cl2: 200, 260, 320, and 400mg).
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Figure 6. Estimates of pore volume utilized for microspheres prepared with varying formulation parameters. The fraction of pore volume
utilized for self-healing encapsulation was estimated by self-healing microsphere porosity (measured by mercury porosimetry) and
assuming concentration of lysozyme in pores for encapsulation equaled external solution concentration (i.e., unity partitioning). Four SM-
formulations were created with A) differing levels of MgCO3 suspended in the organic phase with 200mL inner water phase volume and
320mgmL1 polymer concentration, B) differing volumes of inner water phase volume with no MgCO3 and 320mgmL1 polymer
concentration, and C) differing amounts of PLGA (50:50, i.v.¼0.57 dL g1) in 1mL CH2Cl2 with suspended 4.8mg MgCO3 and 200mL
inner water phase volume.
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www.mbs-journal.deloading after healing. Thus, inmost of the formulations, up
to 75% of the available pore volume appears to go
unutilized. As the same loading for SH particles has been
observed for vastly different size loading molecules
(i.e., 2 million Da dextran vs 10 kDA dextran),[18] it is
believed that this unused porosity is not due to size
limitations of the pore network, but because of some other
phenomenon. An alternative explanation is that most
of the pores were reached by the protein and, because of
large internal polymer surface and increase in entropy of
pore water, a decrease in protein partitioning into the pore
volume (i.e., partition coefficient <1) occurred. Further
experimental and theoretical analysis will be necessary toMacromol. Biosci. 20
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.comresolve whether these two possibilities or some combina-
tion of the two are dominant. Two formulations clearly
different from the rest were microspheres prepared from
very low inner water phase (6% pores utilized) and those
prepared using polymer concentration (30%). The low
fraction of pores for the low inner water phase volume
microspheres couldhave resulted from theproximity to the
low percolation threshold and/or the reduced level of
trehalose used to create the percolating pore network. The
high polymer concentration used in the formulation was
expected to cause more rapid hardening of the polymer,
causing an artificially high e and entrapping a larger
fraction of the osmotically active trehalose.13, 13, 1700–1710
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Figure 7. Controlled release of lysozyme from self-healingmicrospheres frommicrospheres created using differing formulation parameters
during blank PLGA microspheres preparation. Formulations were created with A) differing levels of MgCO3 in the organic phase: 0% (~),
1.5% (*), 4.3% (^), and 11.0% (&), B) differing volumes of inner water phase solution (trehalose in PBS, pH 7.4): 25mL (*), 100mL (~), 200mL
(^), and 350 mL (&), or C) using a constant base amount (4.8mg) but differing amounts of PLGA (50:50, i.v.¼0.57 dL g1) in 1mL CH2Cl2:
200mg (*), 260mg (~), 320mg (^), and 400mg (&). Data in (A) with dashed lines are replotted from Reinhold et al.[1] for completeness.
www.mbs-journal.de
S. E. Reinhold, S. P. Schwendeman
17083.4. Release Kinetics of PLGA-Encapsulated Lysozyme
The release rate of theparticles (Figure 7) directly correlated
with the amount of base used to create the blank particles
(Figure7A).As seen inTable1, theamount released fromthe
microspheres after 28dwas (% SEM) 30 1% (0%MgCO3),
41 1% (1.5% MgCO3), 51 4% (4.3% MgCO3), and 57 4%
(11.0% MgCO3). Increases in base content resulted in
increased burst release over the first couple of days. All
formulations released continuously over about 14 d and
then reached a lag period of very low or no release. Mostly
soluble protein remained in thepolymer at 28d (seebelow).
For changes in innerwaterphasevolume, the28-dreleaseof
these formulations all released similarly, between 24 and
34%of lysozymebyDay28 (Figure7B). Theamount released
from themicrospheres after 28 dwas (% SEM) 29.7 0.3%
(25 mL), 25.9 0.3% (100 mL), 33 2% (200 mL), and
24.5 0.6% (350 mL). For formulations with varying
polymer concentration, like the resulting polymer e of
theSHmicrospheres (seeabove), the28-dreleaseshowedno
immediately obvious trend (Figure 7C). The highest release
rate was from the 400 mg-PLGA formulation, while the
slowest and least released over 28 d was the 260 mg-PLGA
formulation. The amount released from the microspheres
after 28 d was (% SEM) 34.4 0.3% (200mg), 20.6 0.9%
(260mg), 46.6 0.5% (320mg), and 57 2% (400mg). As
increased e and loading is expected to increase release rate,
thedip in the rate of the260mg-polymer formulation could
have resulted from its low e (61%) with similar loading to
the 200 and 320mg formulations. By contrast, the 400mg-
polymer formulation, despite having lower e (65%) than the
320mg formulation (73%), had a significantly higher
lysozyme loading (10% vs. 8%). It should be noted that
the microparticles displayed a lag phase, as has been
reported previously,[23] which for these formulations went
past the final release point tested. Complete release of theMacromol. Biosci. 201
 2013 WILEY-VCH Verlag GmbHencapsulated protein from thebiodegradablemicroparticle
is expected to take place after the 28 d test point.3.5. Recovery and Stability of Lysozyme After Release
In addition to the evaluation of release kinetics, the
encapsulated lysozyme was recovered by extraction at
the end of the evaluated 28-d release period to determine
the physical stability and activity of the lysozyme
remaining in the polymer. The amount of protein remain-
ing, including soluble monomer and insoluble aggregates,
was quantified, as displayed in Table 1. No soluble
aggregate was observed in the samples by SEC-HPLC. Thus,
monomeric content listed in the table also refers to soluble
protein content. As seen in the table, essentially all the
proteinwas recoveredbetween released, remaining soluble
and remaining insoluble enzyme as the mass balance was
close to 100% inmost cases. In addition,most of the protein
was still soluble monomeric protein at the end of the 28 d
incubation. As expected, the least insoluble protein and
most complete recovery was observed in the samples with
the highest MgCO3 content (4.3 and 11%), which is
consistent with our past experience with this enzyme in
this type of PLGA with this base in cylindrical implants.[30]
Moreover, lysozyme is a relatively stable protein in PLGA,
with very little aggregation tendency, compared with
albumin.[30] The one exception was the formulation with
the very phase volume ratio (25mLmL1), which exhibited
11% insoluble aggregate remaining in the polymer at the
end of the release period. This is likely because of themuch
lower loading of this specimen, which results in lower
buffering by the protein and should a constant level of
protein be damaged at an interface, then a correspondingly
higher fraction of protein would be damaged in this
instance.3, 13, 1700–1710
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Figure 8. Specific activity of lysozyme remaining in various microparticle formulations after 28 d release. Formulations of blank particles
were created with A) differing levels of MgCO3 in the organic phase: 0, 1.5, 4.3, and 11.0%, B) differing volumes of inner water phase solution
(trehalose in PBS, pH 7.4): 25, 100, 200, and 350 mL, or C) using differing amounts of PLGA (50:50, i.v.¼0.57 dL g1) in 1mL CH2Cl2: 200, 260,
320, and 400mg (% specific activity was calculated as a percentage of the specific activity of fresh, unencapsulated lysozyme).
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www.mbs-journal.deSimilarly, in most cases >90% of the remaining soluble
protein after 28 d of release was enzymatically active, as
shown in Figure 8. The important exception was the
formulation with the very low inner water phase volume
ratio (25mLmL1). Similar to the elevated aggregation in
this sample (Table 1), a much lower activity in the
remaining protein was observed. It is noted that in the
samples with the higher level of base loaded (4.3 and 11%),
>97% of monomeric protein and full enzymatic activity
was observed after 28 d release. This data strongly supports
the conclusion that the SHmethod is very mild in terms of
protecting proteins during encapsulation, as has been
reported.[18,21,22] We note that MgCO3 and related basic
excipients (Mg(OH)2 and ZnCO3) have been studied
extensively for development of biodegradable polymer
delivery systems. Heller[31] pioneered theuse ofMg(OH)2 in
poly(ortho esters) for stabilizing the ortho ester bond for
long-term controlled release, many later formulations of
which were evaluated in the clinic. Similarly ZnCO3 was
incorporated into the commercial Nutropin Depot.[3] We
have also monitored histology at the injection site of PLGA
containing MgCO3 and found negligible increases in
inflammation.[32] Therefore, we continue to incorporate
this class of excipients into PLGA particles to control both
microclimate pH[23] and increase release of protein.[14]4. Conclusions
In closing, pore-forming excipient loading and e are clearly
key parameters that require attention during encapsula-
tion by the novel SH method. Porosity values in the
neighborhood of 60 to 70% appeared to work well for
loading high levels of protein by the passive encapsulation
method and a variety of pore forming substances could be
used to successfully prepared SH-microspheres for elevated
loading, as demonstrated with BSA studies. Release andMacromol. Biosci. 20
 2013 WILEY-VCH Verlag Gmwww.MaterialsViews.comstability of a model enzyme, lysozyme, was excellent in
certain formulations (e.g., with 4.3% MgCO3) for over two
weeks, although improvements will be needed to accom-
plish continuous release beyond this timepoint and release
the entire protein. Future studies will also need to focus on
mapping the pore network of protein as it enters the SH
microspheres, to reach a higher fraction of pores in the
polymer, and to determine methods for active loading
of pharmaceutical proteins to reduce losses of high-
cost human recombinant proteins, commonly found in
pharmaceutical products.
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